相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antisense Oligonucleotide Reverses Leukodystrophy in Canavan Disease Mice
Vanessa Hull et al.
ANNALS OF NEUROLOGY (2020)
Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria
Sagar Agarwal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
RNA Interference for the Masses? siRNA Targeting PCSK9 Promises Prevention of Cardiovascular Disease
Jonathan K. Watts et al.
NUCLEIC ACID THERAPEUTICS (2020)
End Points for Clinical Trials in Primary Hyperoxaluria
Dawn S. Milliner et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care
David C. Schorling et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2020)
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Eliane Sardh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity
Kyle D. Wood et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2019)
Assessment of the functional impact on the pre-mRNA splicing process of 28 nucleotide variants associated with Pompe disease in GAA exon 2 and their recovery using antisense technology
Elisa Goina et al.
HUMAN MUTATION (2019)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial
Kausik K. Ray et al.
JAMA CARDIOLOGY (2019)
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
J. Kim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
Lawrence A. Leiter et al.
DIABETES CARE (2019)
Treating Disease at the RNA Level with Oligonucleotides
Arthur A. Levin
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Viltotarsen for the treatment of Duchenne muscular dystrophy
R. R. Roshmi et al.
DRUGS OF TODAY (2019)
Effectiveness and Safety of Inclisiran, A Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9
Gopal Chandra Ghosh et al.
AMERICAN JOURNAL OF CARDIOLOGY (2018)
Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria
Chengjung Lai et al.
MOLECULAR THERAPY (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility
Jayesh A. Kulkarni et al.
NUCLEIC ACID THERAPEUTICS (2018)
Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management
Dhrubajyoti Bandyopadhyay et al.
JOURNAL OF LIPIDS (2018)
Inhibiting neutral amino acid transport for the treatment of phenylketonuria
Adam M. Belanger et al.
JCI INSIGHT (2018)
Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective
Christopher P. Austin et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Exon skipping: a first in class strategy for Duchenne muscular dystrophy
Erik H. Niks et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy
N. N. Singh et al.
GENE THERAPY (2017)
Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology
Elisa Goina et al.
MOLECULAR THERAPY (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides
Annemieke Aartsma-Rus
NUCLEIC ACID THERAPEUTICS (2017)
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Annemieke Aartsma-Rus et al.
NUCLEIC ACID THERAPEUTICS (2017)
The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2017)
Molecular Mechanisms of Antisense Oligonucleotides
Stanley T. Crooke
NUCLEIC ACID THERAPEUTICS (2017)
Antisense Oligonucleotides Promote Exon Inclusion and Correct the Common c.-32-13T>G GAA Splicing Variant in Pompe Disease
Erik van der Wal et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells
Erik van der Wal et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Delivery is key: lessons learnt from developing splice-switching antisense therapies
Caroline Godfrey et al.
EMBO MOLECULAR MEDICINE (2017)
Metabolism of 13C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase
Xingsheng Li et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2016)
Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia
P. Barton Duell et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
Xiaohong Yang et al.
JOURNAL OF LIPID RESEARCH (2016)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
The prevalent deep intronic c. 639+919 G>A GLA mutation causes pseudoexon activation and Fabry disease by abolishing the binding of hnRNPA1 and hnRNP A2/B1 to a splicing silencer
Bruno Palhais et al.
MOLECULAR GENETICS AND METABOLISM (2016)
Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1
Chaitali Dutta et al.
MOLECULAR THERAPY (2016)
From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides
Atze J. Bergsma et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders
Maria Francisca Coutinho et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II
Liliana Matos et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2015)
Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
Aurelie Goyenvalle et al.
NATURE MEDICINE (2015)
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
Raul D. Santos et al.
EUROPEAN HEART JOURNAL (2015)
Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist's Perspective
Kendall S. Frazier
TOXICOLOGIC PATHOLOGY (2015)
Data insupport of a functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II
Liliana Matos et al.
DATA IN BRIEF (2015)
Antisense Oligonucleotide-Based Therapy in Human Erythropoietic Protoporphyria
Vincent Oustric et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2014)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
Antisense Mediated Splicing Modulation For Inherited Metabolic Diseases: Challenges for Delivery
Belen Perez et al.
NUCLEIC ACID THERAPEUTICS (2014)
A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications
Peter Jaerver et al.
NUCLEIC ACID THERAPEUTICS (2014)
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Fritz Eckstein
NUCLEIC ACID THERAPEUTICS (2014)
Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo-Controlled Study of Healthy Volunteers
JoAnn D. Flaim et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe Disease
Nicholas P. Clayton et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2014)
Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl-Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates
Frank Rigo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Mipomersen Sodium: First Global Approval
Philip Hair et al.
DRUGS (2013)
Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option
Belen Perez et al.
EPILEPSIA (2013)
Splice Modulating Therapies for Human Disease
Pietro Spitali et al.
CELL (2012)
Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
Evan A. Stein et al.
CIRCULATION (2012)
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
Maartje E. Visser et al.
EUROPEAN HEART JOURNAL (2012)
Antisense oligonucleotide corrects splice abnormality in hereditary myopathy with lactic acidosis
Petter Schandl Sanaker et al.
GENE (2012)
Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
Mary P. McGowan et al.
PLOS ONE (2012)
Pseudoexon Exclusion by Antisense Therapy in 6-Pyruvoyl-Tetrahydropterin Synthase Deficiency
Sandra Brasil et al.
HUMAN MUTATION (2011)
Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease
Dariusz Dziedzic et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2010)
Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses
Xenia Kaidonis et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Antisense Oligonucleotide Treatment for a Pseudoexon-Generating Mutation in the NPC1 Gene Causing Niemann-Pick Type C
Laura Rodriguez-Pascau et al.
HUMAN MUTATION (2009)
Functional Analysis of Three Splicing Mutations Identified in the PMM2 Gene: Toward a New Therapy for Congenital Disorder of Glycosylation type IA
Ana I. Vega et al.
HUMAN MUTATION (2009)
Propionic and methylmalonic acidemia:: Antisense therapeutics for intronic variations causing aberrantly spliced messenger RNA
A. Rincon et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
RNAi-mediated inhibition of the glucosylceramide synthase (GCS) gene:: A preliminary study towards a therapeutic strategy for Gaucher disease and other glycosphingolipid storage diseases
Anna Diaz-Font et al.
BLOOD CELLS MOLECULES AND DISEASES (2006)
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
John J. P. Kastelein et al.
CIRCULATION (2006)
Aberrant splicing in the ocular albinism type 1 gene (OA1/GPR143) is corrected in vitro by morpholino antisense oligonucleotides
F Vetrini et al.
HUMAN MUTATION (2006)
Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism
JP Sheehan et al.
BIOCHEMISTRY (2001)
分享论文
